(Albany, US) September 21, 2026 – DelveInsight’s, “Age-Related Macular Degeneration Pipeline Insight 2026” report provides comprehensive insights about 90+ companies and 100+ pipeline drugs in the Age-Related Macular Degeneration pipeline landscape. It covers the Age-Related Macular Degeneration pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates in the Age-Related Macular Degeneration Pipeline? @ https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-pipeline-insight
Key Takeaways from the Age-Related Macular Degeneration Pipeline Report
Want to know which companies are leading innovation in Age-Related Macular Degeneration? @ Age-Related Macular Degeneration Clinical Trials Assessment
The Age-Related Macular Degeneration Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Age-Related Macular Degeneration Pipeline Report also highlights the unmet needs with respect to the Age-Related Macular Degeneration.
Age-Related Macular Degeneration Overview
Age-related macular degeneration (AMD) is a progressive disorder of the macula and a leading cause of central vision loss in the elderly population. It primarily affects the outer retina, including photoreceptors and the retinal pigment epithelium (RPE), with early accumulation of drusen indicating impaired cellular waste clearance. As the disease advances, chronic inflammation, reduced choroidal blood flow, and RPE dysfunction contribute to photoreceptor degeneration and vision decline. Clinically, AMD progresses from early to late stages, manifesting as the slower dry form (geographic atrophy) or the more aggressive wet (neovascular) form driven by abnormal blood vessel growth. Patients typically experience central visual disturbances such as blurriness, distortion, or scotomas, while peripheral vision remains preserved, with symptoms often worsening rapidly in wet AMD due to fluid leakage or hemorrhage.
Age-Related Macular Degeneration Emerging Drugs Profile
Elamipretide is a mitochondria-targeted peptide developed to enhance cellular energy generation and limit oxidative stress, both of which play a significant role in age-related macular degeneration. It acts by stabilizing cardiolipin within the inner mitochondrial membrane, thereby supporting the function of photoreceptors and retinal pigment epithelium cells. In AMD, especially the dry form, this approach is intended to slow retinal deterioration and help maintain visual function over time. The therapy is currently under evaluation in a Phase III clinical trial for patients with age-related macular degeneration.
4D-150 is an investigational intravitreal gene therapy being developed for neovascular (wet) age-related macular degeneration (AMD). It uses a customized AAV vector to deliver genes encoding anti-VEGF biologics, enabling sustained intraocular production of therapeutic proteins. By providing long-term suppression of VEGF, it aims to reduce treatment burden and control retinal fluid and neovascularization. The therapy is currently in Phase III stage of its clinical development.
MK-8748 (Tiespectus) is an investigational bispecific antibody being developed for neovascular (wet) age-related macular degeneration (AMD). It simultaneously activates the Tie2 pathway and inhibits vascular endothelial growth factor (VEGF), targeting vascular instability and leakage in the retina. This dual mechanism aims to stabilize retinal blood vessels, reduce fluid accumulation, and preserve visual function. The therapy is currently being evaluated in a pivotal Phase IIb/III clinical trial (MALBEC) for patients with wet AMD.
SAR402663 is an investigational one-time intravitreal gene therapy being developed for neovascular (wet) age-related macular degeneration (AMD). It delivers genetic material encoding soluble FLT01, which inhibits vascular endothelial growth factor (VEGF) to suppress abnormal blood vessel growth. By reducing vascular leakage and retinal damage, it aims to preserve vision and address the underlying disease pathology. The therapy is currently in Phase II clinical evaluation and has received fast track designation from the FDA.
Xelafaslatide is an investigational first-in-class small molecule Fas inhibitor being developed for geographic atrophy associated with dry age-related macular degeneration (AMD). It works by blocking Fas-mediated cell death pathways, thereby protecting retinal cells such as photoreceptors from degeneration. By preserving retinal structure, it aims to slow disease progression and maintain visual function. The therapy is currently being evaluated in a global Phase II clinical trial for patients with dry AMD-related geographic atrophy.
HG202 is an investigational CRISPR/Cas13-based RNA-editing therapy being developed for neovascular (wet) age-related macular degeneration (AMD). It utilizes a single AAV vector to deliver RNA-editing machinery that selectively knocks down VEGF-A mRNA, a key driver of abnormal blood vessel growth. By reducing VEGF expression, it aims to inhibit choroidal neovascularization and provide a durable, potentially one-time treatment option. The therapy is currently in early Phase I clinical evaluation following FDA IND clearance.
If you’re tracking ongoing Age-Related Macular Degeneration Clinical trials, this press release is a must-read @ Age-Related Macular Degeneration Treatment Drugs
Age-Related Macular Degeneration Companies
Stealth BioTherapeutics, Sanofi, Merck, HuidaGene Therapeutics, ONL Therapeutics, Molecular Therapeutics, Evergreen Therapeutics, Caregen Co. Ltd., SCAI Therapeutics, Frontera Therapeutics, Chengdu Origen Biotechnology Co., Ltd., BenoBio, Skyline Therapeutics, Perceive Biotherapeutics, Sinocelltech Ltd., Tangram Therapeutics, Character Biosciences, Amarna Therapeutics, Avirmax Biopharma, Galimedix Therapeutics, Rallybio, Ikarovec, 4P Pharma, Surrozen, Beacon Therapeutics, Ray Therapeutics and others.
The Age-Related Macular Degeneration Pipeline report provides insights into
Age-Related Macular Degeneration pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Age-Related Macular Degeneration Products have been categorized under various Molecule types such as
The Age-Related Macular Degeneration Pipeline Report covers it all @ Age-Related Macular Degeneration Market Drivers and Barriers, and Future Perspectives
Scope of the Age-Related Macular Degeneration Pipeline Report
Discover what’s next for the Age-Related Macular Degeneration Treatment landscape in this detailed analysis @ Age-Related Macular Degeneration Emerging Drugs and Major Players
Table of Content
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-pipeline-insight
